We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Scientists Develop Colon Cancer-Detecting Blood Test
News

Scientists Develop Colon Cancer-Detecting Blood Test

Scientists Develop Colon Cancer-Detecting Blood Test
News

Scientists Develop Colon Cancer-Detecting Blood Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Scientists Develop Colon Cancer-Detecting Blood Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

To date, physicians have relied on colonoscopies and fecal occult blood testing (FOBT) to identify potential cases of early stage colon cancer. However, the unpleasantness and discomfort associated with colonoscopies and the limited reliability of other screening tests cause many patients to avoid testing.

“When patients avoid testing, they also avoid the opportunity to detect the cancer at its earliest and most survivable stages,” says Tom Boyd, CEO of EDP Biotech. “This means patients are truly putting their lives at risk. We saw an opportunity to save lives if we could help physicians better identify which of their patients were most in need of a colonoscopy or other testing.”

ColoMarker provides that function as a simple blood test. The test identifies elevated levels of a biomarker in the bloodstream associated with the presence of colorectal cancers. When an elevated result is received, physicians can consult with their patients on the need for additional testing to aid in a diagnosis, prognosis, or treatment plan.

Pre-clinical testing of ColoMarker has shown a greater than 99% accuracy rate for detecting colon cancer in the Stages I, II, and III.

The company also was recently awarded a grant from the United States government for work on further development and testing of ColoMarker. The Qualifying Therapeutic Discovery Project (QTDP) grant is awarded to assist bio-tech companies showing significant potential in their work to develop new therapies and making advances in the fight to cure cancer. By debuting ColoMarker in the exhibit halls of the Medica trade fair, EDP Biotech hopes to bring that same awareness of ColoMarker’s potential to research laboratories and medical practices across Europe.

http://www.businesswire.com/news/home/20101117006929/en/Colon-Cancer-Detecting-Blood-Test-Previewed-Medica-Trade

Advertisement